Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

MKSAP: 35-year-old woman with constipation

mksap
Meds
June 8, 2019
Share
Tweet
Share

Test your medicine knowledge with the MKSAP challenge, in partnership with the American College of Physicians.

A 35-year-old woman is evaluated for constipation. She reports passage of hard stool every 3 to 4 days and associated bloating. Her symptoms have been present for more than 10 years and have progressed gradually. Trials of over-the-counter fiber supplementation and polyethylene glycol worsened the bloating, prompting discontinuation. Senna tea was ineffective. Bisacodyl caused abdominal cramping. She is otherwise healthy and currently takes no medication.

On physical examination, vital signs and other findings are normal.

Which of the following is the most appropriate treatment?

A. Lactulose
B. Linaclotide
C. Methylnaltrexone
D. Rifaximin

MKSAP Answer and Critique

The correct answer is B. Linaclotide.

Linaclotide is the most appropriate treatment for this patient. Linaclotide is a peripherally acting guanylate cyclase-C receptor agonist that is FDA approved for the treatment of chronic idiopathic constipation in adults. Linaclotide increases intracellular and extracellular cyclic guanosine monophosphate, which results in chloride and bicarbonate secretion into intestinal lumen, increasing intestinal fluid content and accelerated transit time. Its superiority to placebo in the treatment of constipation was demonstrated in two 12-week, high-quality randomized controlled trials. Diarrhea occurred in 16% of patients receiving linaclotide (compared to 4.7% in those receiving placebo) in the 12-week clinical trials. The potential for diarrhea can be minimized by taking linaclotide on an empty stomach, ideally 30 minutes before the first meal of the day. Plecanatide is the second guanylate cyclase-C receptor agonist to receive FDA approval for the treatment of chronic idiopathic constipation. Diarrhea was also the most commonly reported side effect of plecanatide therapy in the 12-week clinical trials (5% versus 1% in the placebo group). Lubiprostone, a chloride channel agonist, is a third agent with FDA approval for the treatment of chronic idiopathic constipation. The most common side effects reported in clinical trials were nausea, reported by 29% of patients taking lubiprostone, and diarrhea, reported by 12%. The efficacy and safety of linaclotide, plecanatide, and lubiprostone have not been established in patients aged younger than 18 years nor in pregnant patients.

Because of cost effectiveness, over-the-counter laxatives, such as fiber supplements, polyethylene glycol, and bisacodyl, should be pursued first in patients with constipation, but they were ineffective in this patient.

Osmotic laxatives include magnesium hydroxide, lactulose, sorbitol, and polyethylene glycol (PEG); clinical trials have demonstrated the superiority and safety of PEG. The patient tried over-the-counter PEG, and it was poorly tolerated due to bloating. Substituting another, less effective, osmotic agent (for example, lactulose) will lead to similar adverse effects without relieving constipation.

Methylnaltrexone, an injectable peripheral opioid antagonist that does not cross the blood-brain barrier, is very effective in treating opioid-induced constipation without adversely affecting analgesia. Bowel obstruction is an absolute contraindication to methylnaltrexone. Because this patient does not have opioid-induced constipation, methylnaltrexone is an inappropriate choice.

Rifaximin is a nonabsorbable antibiotic used in the treatment of irritable bowel syndrome predominated by diarrhea, hepatic encephalopathy, and travelers’ diarrhea. It has no proven efficacy in chronic idiopathic constipation and is therefore not indicated in this patient.

Key Point

  • Linaclotide is a peripherally acting guanylate cyclase-C receptor agonist that is FDA approved for the treatment of chronic idiopathic constipation in adults with symptoms refractory to first-line therapies.

This content is excerpted from MKSAP 18 with permission from the American College of Physicians (ACP). Use is restricted in the same manner as that defined in the MKSAP 18 Digital license agreement. This material should never be used as a substitute for clinical judgment and does not represent an official position of ACP. All content is licensed to KevinMD.com on an “AS IS” basis without any warranty of any nature. The publisher, ACP, shall not be liable for any damage or loss of any kind arising out of or resulting from use of content, regardless of whether such liability is based in tort, contract or otherwise.

Prev

The journey from hand surgeon to entrepreneur

June 7, 2019 Kevin 1
…
Next

A father and grandfather: A patient's life lived in full

June 8, 2019 Kevin 0
…

ADVERTISEMENT

Tagged as: Gastroenterology, Medications

Post navigation

< Previous Post
The journey from hand surgeon to entrepreneur
Next Post >
A father and grandfather: A patient's life lived in full

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

More by mksap

  • a desk with keyboard and ipad with the kevinmd logo

    MKSAP: 26-year-old man with back pain

    mksap
  • a desk with keyboard and ipad with the kevinmd logo

    MKSAP: 36-year-old man with abdominal cramping, diarrhea, malaise, and nausea

    mksap
  • a desk with keyboard and ipad with the kevinmd logo

    MKSAP: 52-year-old woman with osteoarthritis of the right hip

    mksap

Related Posts

  • a desk with keyboard and ipad with the kevinmd logo

    MKSAP: 60-year-old woman with persistent constipation

    mksap
  • a desk with keyboard and ipad with the kevinmd logo

    MKSAP: 45-year-old woman with type 2 diabetes mellitus

    mksap
  • How one woman prevented a pharmaceutical disaster

    James Essinger and Sandra Koutzenko
  • 3 ways we’ve failed woman who breastfeed

    Joanna Buscemi, PhD
  • A skin-lightening cream put a woman into a coma. How can that happen?

    Anna Almendrala
  • Why you should think twice about prescribing antibiotics

    Rich Rodriguez, MD

More in Meds

  • Why does rifaximin cost 95 percent more in the U.S. than in Asia?

    Jai Kumar, MD, Brian Nohomovich, DO, PhD and Leonid Shamban, DO
  • A world without antidepressants: What could possibly go wrong?

    Tomi Mitchell, MD
  • The truth about GLP-1 medications for weight loss: What every patient should know

    Nisha Kuruvadi, DO
  • The hidden bias in how we treat chronic pain

    Richard A. Lawhern, PhD
  • Biologics are not small molecules: the case for pre-allergy testing in an era of immune-based therapies

    Robert Trent
  • The anesthesia spectrum: Guiding patients through comfort options in oral surgery

    Dexter Mattox, MD, DMD
  • Most Popular

  • Past Week

    • The silent toll of ICE raids on U.S. patient care

      Carlin Lockwood | Policy
    • Why recovery after illness demands dignity, not suspicion

      Trisza Leann Ray, DO | Physician
    • Addressing the physician shortage: How AI can help, not replace

      Amelia Mercado | Tech
    • Bureaucracy over care: How the U.S. health care system lost its way

      Kayvan Haddadan, MD | Physician
    • Why does rifaximin cost 95 percent more in the U.S. than in Asia?

      Jai Kumar, MD, Brian Nohomovich, DO, PhD and Leonid Shamban, DO | Meds
    • Why medical students are trading empathy for publications

      Vijay Rajput, MD | Education
  • Past 6 Months

    • What’s driving medical students away from primary care?

      ​​Vineeth Amba, MPH, Archita Goyal, and Wayne Altman, MD | Education
    • Residency as rehearsal: the new pediatric hospitalist fellowship requirement scam

      Anonymous | Physician
    • The broken health care system doesn’t have to break you

      Jessie Mahoney, MD | Physician
    • Make cognitive testing as routine as a blood pressure check

      Joshua Baker and James Jackson, PsyD | Conditions
    • A faster path to becoming a doctor is possible—here’s how

      Ankit Jain | Education
    • The hidden bias in how we treat chronic pain

      Richard A. Lawhern, PhD | Meds
  • Recent Posts

    • When errors of nature are treated as medical negligence

      Howard Smith, MD | Physician
    • Physician job change: Navigating your 457 plan and avoiding tax traps [PODCAST]

      The Podcast by KevinMD | Podcast
    • The hidden chains holding doctors back

      Neil Baum, MD | Physician
    • Hope is the lifeline: a deeper look into transplant care

      Judith Eguzoikpe, MD, MPH | Conditions
    • Why medical students are trading empathy for publications

      Vijay Rajput, MD | Education
    • From hospital bed to harsh truths: a writer’s unexpected journey

      Raymond Abbott | Conditions

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

Leave a Comment

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • The silent toll of ICE raids on U.S. patient care

      Carlin Lockwood | Policy
    • Why recovery after illness demands dignity, not suspicion

      Trisza Leann Ray, DO | Physician
    • Addressing the physician shortage: How AI can help, not replace

      Amelia Mercado | Tech
    • Bureaucracy over care: How the U.S. health care system lost its way

      Kayvan Haddadan, MD | Physician
    • Why does rifaximin cost 95 percent more in the U.S. than in Asia?

      Jai Kumar, MD, Brian Nohomovich, DO, PhD and Leonid Shamban, DO | Meds
    • Why medical students are trading empathy for publications

      Vijay Rajput, MD | Education
  • Past 6 Months

    • What’s driving medical students away from primary care?

      ​​Vineeth Amba, MPH, Archita Goyal, and Wayne Altman, MD | Education
    • Residency as rehearsal: the new pediatric hospitalist fellowship requirement scam

      Anonymous | Physician
    • The broken health care system doesn’t have to break you

      Jessie Mahoney, MD | Physician
    • Make cognitive testing as routine as a blood pressure check

      Joshua Baker and James Jackson, PsyD | Conditions
    • A faster path to becoming a doctor is possible—here’s how

      Ankit Jain | Education
    • The hidden bias in how we treat chronic pain

      Richard A. Lawhern, PhD | Meds
  • Recent Posts

    • When errors of nature are treated as medical negligence

      Howard Smith, MD | Physician
    • Physician job change: Navigating your 457 plan and avoiding tax traps [PODCAST]

      The Podcast by KevinMD | Podcast
    • The hidden chains holding doctors back

      Neil Baum, MD | Physician
    • Hope is the lifeline: a deeper look into transplant care

      Judith Eguzoikpe, MD, MPH | Conditions
    • Why medical students are trading empathy for publications

      Vijay Rajput, MD | Education
    • From hospital bed to harsh truths: a writer’s unexpected journey

      Raymond Abbott | Conditions

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Leave a Comment

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...